When was Mid Atlantic Bio Angels founded?

Mid Atlantic Bio Angels was founded in 2012.

Where is Mid Atlantic Bio Angels' headquarters located?

Mid Atlantic Bio Angels' headquarters is located in New York City (United States).

How many companies has Mid Atlantic Bio Angels invested in?

Mid Atlantic Bio Angels has invested in 12 companies, including Immunomic Therapeutics & Virion Therapeutics.

Which companies has Mid Atlantic Bio Angels invested in lately?

Astrocyte Pharmaceuticals & Hilltop Bio are the latest investments by Mid Atlantic Bio Angels.

What sectors does Mid Atlantic Bio Angels focus on for investments?

Top sectors in Mid Atlantic Bio Angels' portfolio are Life Sciences (8 investments) and High Tech (3 investments).

How many exits has Mid Atlantic Bio Angels been involved in?

Mid Atlantic Bio Angels' portfolio has seen 1 acquisition.

Mid Atlantic Bio Angels - 2026 Investor Profile, Portfolio, Team & Investment Trends

1. Immunomic Therapeutics

Immunomic Therapeutics develops lysosomal-associated membrane protein-based vaccines for the treatment of allergy and cancer. The company has partnered with Astellas to develop vaccines for Japnese red cedar (Phase 1), peanut allergy (Phase 1). Its immunology pipeline includes AST-VAC1 to treat acute myeloid leukemia (AML) (Phase 2); LAMP-Vax + pp64 DC therapy for brain cancer (Phase 1); ATTAC-II clinical trial (Phase II), etc.

Key facts about Immunomic Therapeutics

Founded Year: 2005
Location: Rockville (United States)
Stage: Series B
Total Funding till date: $104M
Employee Count: 51 as on Dec 31, 2022
Investors: Defense.gov, Brainchild and 7 Others
Latest Funding Round: Series B, May 29, 2025, $*****
Highlight: Editors' Pick

2. Virion Therapeutics

Developing T cell immunotherapies for cancer and chronic infectious diseases. The company is a clinical-stage biopharmaceutical company focused on revolutionizing immunotherapy treatment. They develop novel, adaptable, and accessible CD8+ T cell-based technologies. Their platform combines innovative and established approaches to elicit a superior CD8+ T cell response. Novel genetically encoded checkpoint modifiers are delivered alongside optimized target-specific antigens via an immunogenic and adaptable viral vector platform that promotes potent, prolonged, and broad CD8+ T cell responses. The company's technology has potential applications across a range of cancers and chronic infectious diseases, with a lead product under investigation as a potential functional cure for the treatment of chronic hepatitis B virus (HBV). They utilize a VIACT™ platform, combining genetically encoded checkpoint modifiers with intelligently selected and optimized target antigens, inserted into heterologous chimpanzee adenoviral vectors.

Key facts about Virion Therapeutics

Founded Year: 2018
Location: Newark (United States)
Stage: Series A
Total Funding till date: $5.23M
Employee Count: 8 as on Jul 31, 2026
Investors: Alliance of Angels, Robin Hood Ventures and 5 Others
Latest Funding Round: Conventional Debt, Jun 07, 2021, $*****

3. Elysium Therapeutics

Developing innovative solutions to combat opioid overdose and reduce opioid abuse. This therapeutics company is dedicated to establishing new safety standards in the pharmaceutical industry, specifically addressing the opioid crisis. They focus on creating Safer Medicines that Alleviate Risks and Trauma (SMART) products. Their lead products include a rescue agent designed for synthetic opioid overdoses and an oral overdose protection system. These solutions aim to reduce opioid use disorder, prevent fatal overdoses, and effectively manage pain. The company leverages its expertise to develop novel chemical entities with the potential to receive breakthrough technology designation. They are seeking partners to support their mission of reducing suffering from pain, opioid use disorder, and fatal opioid overdose. Their work has a significant social impact, addressing a critical public health issue.

Key facts about Elysium Therapeutics

Founded Year: 2013
Location: San Francisco (United States)
Stage: Series A
Total Funding till date: $9.94M
Employee Count: 4 as on Jul 31, 2026
Investors: Mesa Verde Venture Partners, Innovations for Impact and 4 Others
Latest Funding Round: Series A, Jan 28, 2026, $*****
Highlight: Editors' Pick

4. FEMSelect

Developer of minimally invasive uterine prolapse system. The company's product, EnPlace is a surgical system for suturing ligaments of the pelvic floor for Pelvic Organ Prolapse (POP). The device is a combination of a nitinol-based anchor and surgical sutures.

Key facts about FEMSelect

Founded Year: 2012
Location: Modi in Maccabim Re ut (Israel)
Stage: Series B
Total Funding till date: $9M
Employee Count: 14 as on Jul 31, 2026
Investors: Triventures, Teal Ventures and 11 Others
Latest Funding Round: Series B, Oct 19, 2022, $*****
Highlight: Editors' Pick

5. Cerus Endovascular

Cerus Endovascular is engaged in the design and development of highly differentiated and proprietary interventional neuroradiology (INR) devices and delivery systems. These devices will have applications in the minimally invasive treatment of neurovascular diseases, particularly intracranial aneurysms.

Key facts about Cerus Endovascular

Founded Year: 2011
Location: Oxford (United Kingdom)
Stage: Acquired
Total Funding till date: $8.21M
Employee Count: 14 as on Dec 31, 2021
Investors: Johnston Associates, Andover and 3 Others
Latest Funding Round: Series A, Aug 26, 2019, $*****
Highlight: Acquired

View the full list of portfolio companies

Mid Atlantic Bio Angels has invested in 12 companies over the last 13 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in Hilltop Bio and most recent follow-on round was in Astrocyte Pharmaceuticals.

Here are Mid Atlantic Bio Angels' Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	0	0
2025	0	0	0
2024	0	0	0
2023	1	1	2
2022	3	0	3
2021	0	1	1
2020	1	0	1
2019	0	1	1
2018	2	0	2
2017	2	0	2

View all investments by Mid Atlantic Bio Angels

Mid Atlantic Bio Angels has made 5 investments in Seed stage with an average round size of $2.18M, 5 investments in Series A stage with an average round size of $4.93M, 1 investment in Conventional Debt stage with an average round size of $3M and 1 investment in Series B stage with an average round size of $9M.

Here are Mid Atlantic Bio Angels' investments by stage:

Stage of entry	No. of Investments
Seed	5
Series A	5
Conventional Debt	1
Series B	1

Note: We have considered here, only first round of investments

View all investments by Mid Atlantic Bio Angels

Mid Atlantic Bio Angels has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, High Tech, Enterprise Applications and Healthcare. Notably, it has invested in 11 Tech companies, 10 Enterprise (B2B) companies, 4 Software companies and at least 4 companies focusing on Tech hardware.

Here are Mid Atlantic Bio Angels' investments by sector:

Sector	No. of Investments
Life Sciences	8
HealthTech	3
High Tech	3
Enterprise Applications	2
Healthcare	2
Others	6

Note: We have considered here, only first round of investments

View all investments by Mid Atlantic Bio Angels

Mid Atlantic Bio Angels has made most investments in United States (9), followed by France where it has made 1 investment.

Here are Mid Atlantic Bio Angels' investments by geography:

Country	No. of Investments
United States	9
France	1
Israel	1
United Kingdom	1

Note: We have considered here, only first round of investments

View all investments by Mid Atlantic Bio Angels

Mid Atlantic Bio Angels has not made any investment in 2026 so far.

Here are the most recent investments by Mid Atlantic Bio Angels:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
Aug 21, 2023	Astrocyte Pharmaceuticals	United States	Series A	2800	Dreavent [+6]
Mar 30, 2023	Hilltop Bio	United States	Seed	6415	-
Oct 19, 2022	FEMSelect	Israel	Series B	8292	New Age Ventures [+7]
Oct 18, 2022	DeepLife	France	Series A	7109	Paris Business Angels [+7]
Aug 25, 2022	The Shape Sensing	United States	Seed	8656	-

See more recent investments made by Mid Atlantic Bio Angels

1 company from Mid Atlantic Bio Angels' portfolio has been acquired. The most recent acquisition was Cerus Endovascular in May 2023 by Stryker for $*****.

Here are Mid Atlantic Bio Angels' portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Cerus Endovascular	May 02, 2023	Jun 06, 2013	Seed	8686

View all acquired companies in Mid Atlantic Bio Angels' portfolio

Mid Atlantic Bio Angels has a team of 1 member located in United States. Mid Atlantic Bio Angels' team does not sit on the board of any company as of now.

View team details of Mid Atlantic Bio Angels

Over the past 13 years, 56 investors have co-invested in Mid Atlantic Bio Angels's portfolio companies. This includes funds and angels.

Invested before Mid Atlantic Bio Angels: HHS, Boston Harbor Angels and 4 others have invested in rounds before Mid Atlantic Bio Angels. There are 2 companies where HHS has invested before Mid Atlantic Bio Angels and 1 company where Boston Harbor Angels has invested before Mid Atlantic Bio Angels.
Top Co-investors of Mid Atlantic Bio Angels: 32 investors entered a company along with Mid Atlantic Bio Angels. These include investors like Keiretsu Capital (3 companies).
Invested after Mid Atlantic Bio Angels: A total of 18 investors have invested in Mid Atlantic Bio Angels's portfolio after their investments. Top Investors include HHS (2 companies) and SBIR (1 company).